Ipsen Strikes Alliance With The Erasmus University Medical Centre Rotterdam

Ipsen (ISIN:FR0010259150) (Paris:IPN) today announced it acquired an international patent application filed on 13th April 2006 owned by Erasmus University Medical Center Rotterdam (Erasmus MC), the Netherlands, for the co-administration of a somatostatin analogue with a growth hormone antagonist for the treatment of acromegaly. The application is based on clinical findings by Professor van der Lely, Head of Endocrinology in the Department of Internal Medicine at Erasmus MC. Preliminary clinical data1 suggest that the combined treatment of acromegaly with monthly long-acting somatostatin analogue(s) and weekly subcutaneous pegvisomant administrations is effective, might increase compliance and could greatly reduce the costs of medical treatment in some patients.